Interviews
CONFIDE: Understanding bowel urgency in CD
6
What were the key findings about bowel urgency in people with CD in confide and do we see the same in other studies?
74
How was the CONFIDE survey set up?
124
What were the key findings about bowel urgency in people with CD in CONFIDE and to we see the same in other studies?
Optimizing short-term goals in UC
6
Which are the most important short-term goals for disease control in UC?
51
Do these overlap with the short-term goals that matter most to patients?
90
How have goals changed over time?
128
What challenges exists with current therapeutic approaches?
173
How can we optimize short-term goals in UC?
Updated guidelines for CD
6
What new treatments are included in the guideline update?
37
What new evidence has supported updates around dietary therapies, and what are the new practice points?
85
Have any recommendations been downgraded?
127
How has language around conventional therapies changed, and why?
214
How can we benchmark treatments?
PROFILE: New data in Crohn's disease
6
What was the PROFILE study, and what was the background?
76
Can you tell us about the aims and objectives?
99
What were the efficacy results presented at ECCO 2024?
220
What were the key safety findings?
311
What are the implications for clinical practice?
VIVID detail: mirikizumab in CD
6
What were the key results for mirikizumab compared to usetkinumab in VIVID-1?
108
How does VIVID-1 compare to other trials such as SEQUENCE?
IBD treatment targets
6
How have treatment targets changed in IBD?
67
What are the most common questions that clinicians have about treatment targets?
121
How do targets from clinical trials translate into clinical practice?
157
Which treatment targets are most important for patients?
ADMIRE-CD: Understanding complex CD features
6
Why are complex perianal fisulas so hard to treat?
64
What is darvadstrocel?
84
What were the key findings from ADMIRE-CD?
127
What are the key takeaways, and implications for clinical practice?
VIVID detail: mirikizumab in CD
6
What is the most frequently asked question about mirikizumab, and how does VIVID-1 help answer that?
54
What is the significance of the VIVID-1 trial design?
117
What was the primary efficacy endpoint?
163
Can you tell us about the key safety findings?
210
What do these results mean for patients?
Combining advanced therapies
6
How many classes of advanced agents are currently on the market for IBD?
46
Is there a biological rationale for combining advanced therapies?
92
What is the most common question clinicians have around combining advanced therapies?
Insights into novel MoA
6
Ozanimod is approved for UC, but what is the general perception about its mechanism of action, and is that the entire story?
47
Can you give us the topline findings that you shared at ECCO 2024?
114
What do these receptors do?
178
How do you think this is going to change the IBD landscape?
Achieving long-term success in UC
6
When thinking about achieving long-term outcomes for real-world patients, what are the key goals?
53
Are we seeing long-term success in the various clinical trial programs?
98
How do we translate long-term clinical data into everyday practice?
143
How can we position mirikizumab in clinical practice?
Gaps in CD assessment and management
6
Are we meeting the needs of people with CD?
42
How do we currently assess CD patients, and is there room for a more holistic approach?
98
What is the impact of fatigue?
166
Are there gaps in treat-to-target strategies for CD?
New agents in IBD
6
What is the mechanism of action of VTX002, and what key Phase 2 results were presented at ECCO 2024?
60
How do these findings compare with other existing treatment options for UC?
121
What is the most common question that clinicians have around new agents?
U-ENDURE: Long-term data in Crohn's disease
6
Can you tell us about the U-ENDURE study?
77
What are the key takeawaya from the long-term data presented at ECCO 2024?
134
Will data continue to be collected for this patient population?
New guselkumab data in UC
6
What do we know about the mechanism of action of guselkumab?
31
How has new data presented at ECCO enhanced the picture?
69
Can you give us the topline results you presented?
146
How does epithelial repair translate into clinical outcomes for patients?
181
What are the most common questions clinicians have about new agents, and how can we address this?
The ECCO 2024 Congress key highlights slide kit
Ask the Expert